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Abstract
Background: During aging, alterations of the intestinal microbial ecosystem can occur contributing to
immunosenescence, inflamm-aging and impairment of intestinal barrier function (increased intestinal permeability;
IP). In the context of a diet-microbiota-IP axis in older subjects, food bioactives such as polyphenols may play a
beneficial modulatory role.
Methods: MaPLE is a project centered on a randomized, controlled cross-over dietary intervention trial
[polyphenol-rich diet (PR-diet) versus control diet (C-diet)] targeted to older people (≥ 60 y) living in a well-
controlled setting (i.e. nursing home). The 8-week interventions are separated by an 8-week wash-out period. Three
small portions per day of selected polyphenol-rich foods are consumed during intervention in substitution of other
comparable products within the C-diet. Biological samples are collected before and after each treatment period to
evaluate markers related to IP, inflammation, vascular function, oxidative stress, gut and blood microbiomics,
metabolomics. A sample size of 50 subjects was defined based on IP as primary outcome.
Discussion: Evidence that increasing the consumption of polyphenol-rich food products can positively affect
intestinal microbial ecosystem resulting in reduced IP and decreased translocation of inflammogenic bacterial
factors into the bloodstream will be provided. The integration of data from gut and blood microbiomics,
metabolomics and other IP-related markers will improve the understanding of the beneficial effect of the
intervention in the context of polyphenols−microbiota−IP interactions. Finally, findings obtained will provide a
proof of concept of the reliability of the dietary intervention, also contributing to future implementations of dietary
guidelines directed to IP management in the older and other at risk subjects.
Trial registration: The trial is registered at (ISRCTN10214981); April 28, 2017.
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Background
Age-associated changes significantly compromise health
status and increase the risk of chronic diseases. Within
these modifications, recent research has been focusing
on those that specifically occur at the gut epithelium
level with impact on intestinal immune homeostasis and
related systemic responses [1]. The maintenance of a
functional intestinal barrier (the functional entity separ-
ating the gut lumen from the inner host) [2], seems to
be of utmost importance to facilitate healthy aging.
Nevertheless, no conclusive evidence exists for a direct
or causal link between the aging process and intestinal
mucosa integrity impairment [3, 4].
The intestine acts both as a barrier (to keep harmful
substances out of the body) and as a selectively perme-
able surface that allows the controlled passage of sub-
stances from the gut lumen through the gut wall and
into the body. This controlled flux across the intestinal
wall is known as intestinal permeability (IP) [2]. Inappro-
priate IP (i.e. loss of control of the influx of substances
from the gut) has been associated with several disorders
and diseases, such as irritable bowel syndrome, inflam-
matory bowel disease, allergy, colon cancer, obesity,
celiac disease, inflammatory joint diseases and neuro-
logic pathologies (e.g. Parkinson’s disease) [5–8]. In this
regard the intestinal microbiota is considered an import-
ant factor in the regulation of IP, in fact, gut microor-
ganisms may directly affect IP through tight junction
modulation [9] and indirectly by contributing to the up/
down regulation of inflammatory processes, which is a
key factor in causing impaired IP [10]. Consequently,
manipulation of the complex intestinal microbial ecosys-
tem (i.e. the microbiota and derived metabolic products)
has been proposed as a novel strategy to maintain/im-
prove normal IP function [2].
Increasing evidence suggests that dietary patterns can
represent a relevant factor in shaping the intestinal
microbiota and modifying the relative abundance of spe-
cific bacterial taxa [11–13]. Consequently, modulating
the concentrations of health-affecting microbial metabo-
lites in the gut such as butyrate [14, 15], has been sug-
gested to preserve tight junction integrity and inhibit
TNF-alpha release, thus maintaining appropriate IP con-
dition [16]. Nutrients are also essential themselves and
malnutrition is associated with increased IP [17].
Older subjects are often characterized by alterations of
the intestinal microbial ecosystem [18, 19], which may
be due to inadequate nutrition, drug treatments and
other age-related factors: all of these seem to contribute
to immunosenescence and inflamm-aging [18, 20].
In the context of a diet-microbiota-IP axis, food bioac-
tives may have a key role in regulating the numerous in-
terconnected processes involved. Particularly, polyphenols
exert antioxidant, anti-inflammatory/immunomodulatory
properties at intestinal and systemic levels, and there is in-
creasing mechanistic evidence suggesting their potential
to modulate IP [21, 22]. In addition, polyphenols are ex-
tensively metabolized by the microbiota and can affect its
composition [13, 23]. The combination of the modulation
of intestinal ecology by polyphenols and the effect on de-
rived microbial metabolites has been shown to improve
inflammatory markers [24]. Taken together, these data
support findings obtained from observational studies in
older subjects suggesting that a high polyphenol diet is
associated with favorable health outcomes [25]. But, well-
controlled intervention studies are still lacking [21].
Aim
The aim of the MaPLE project (Microbiome mAnipula-
tion through Polyphenols for managing Leakiness in the
Elderly) is to evaluate the hypothesis that an increased
intake of polyphenol-rich foods can reduce IP and lower
inflammogenic bacterial factors in the bloodstream pro-
moting an overall protective/beneficial metabolic pheno-
type in older subjects. Three approaches have been
taken; the main study, a dietary intervention randomized
controlled trial described here, combined with pre-
clinical studies in an animal model of aging to test the
impact of the polyphenol-rich diet on IP associated
markers, and also in cultured human intestinal cells
(caco-2) to investigate the capacity of single polyphenols
to modulate IP.
Methods/design
MaPLE RCT: protocol and study design
The MaPLE RCT is a single-blind, randomised, con-
trolled, cross-over trial [polyphenol-rich diet (PR-diet)
versus control diet (C-diet)] in older people (≥ 60 y) liv-
ing in a nursing home. Each intervention period consists
of 8 weeks and is separated by an 8-week wash-out
period in which participants consume their habitual diet
to avoid carry-over effects.
The PR-diet and C-diet were developed to provide ad-
equate and comparable levels of energy and nutrients.
The PR-diet was achieved by replacing three portions
per day of low polyphenol foods/beverages with specific
polyphenol-rich foods/beverages (as detailed below).
During the study, subjects are asked to fast overnight be-
fore each scheduled time-point of blood, urine and feces
collection. In addition, daily menus and weighted food
records (WFRs) are collected throughout the trial. An
overview of the study design is represented in Fig. 1 and
Table 1. The study adhered to SPIRIT guidelines.
Trial status
The trial has been prospectively registered (April 28,
2017; ISRCTN10214981).
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The whole trial has been completed (December 2019);
analyses and data elaboration are still ongoing.
Location
The intervention has been performed at Civitas Vitae
(OIC Foundation, Padua, Italy) which hosts a large num-
ber of older people living in residential care buildings or
in independent residences located in the same area, de-
pending on individual willingness and level of disabil-
ities. The OIC Foundation provides several facilities and
dedicated area for meal preparation. This allows to col-
lect accurate information with regard the composition of
the diets from the recipes used for each of the foods in
the meals delivered daily to the participants. We were
able to accurately assess food intake using weighed food
records in the intervention study.
Participant enrollment
Before recruitment, a meeting with the medical staff and
nurses’ coordinators at OIC Foundation took place in
order to present and widely discuss the aim, methodolo-
gies and technical aspects related to the development
and the management of the MaPLE RCT. After this
meeting, several formal presentations of the project aim
and some general information on the intervention
planned were organized at OIC Foundation for the hosts
and their families. Finally, an accurate evaluation of the
host characteristics was performed in collaboration with
the physicians/geriatricians and nurses’ coordinators to
pre-select based on the verification of the main inclusion
and exclusion criteria (see below) and to identify plaus-
ible candidates for the study. Subjects who were inter-
ested in participating in the study signed an informed
consent reporting all the information on the dietary
intervention, the analysis and protocols that they were
asked to undertake/follow.
More specifically, volunteers were selected according
to the inclusion and exclusion criteria reported below:
Inclusion criteria
 Age ≥ 60 years
 Adequate nutritional status evaluated with Mini
Nutritional Assessment (MNA), score ≥ 24
 Good cognitive status tested with Mini Mental State
Examination (MMSE), score ≥ 24
 Self-sufficiency assessed with validated tests (e.g.
Barthel index – activities of daily living, score ≥ 60)
 Increased intestinal permeability evaluated by serum
zonulin level
Exclusion criteria
 Celiac disease
 Severe liver disease with cirrhosis
 Severe renal insufficiency (dialysis)
 Presence of severe Chronic Obstructive Pulmonary
Disease (COPD; oxygen therapy for many hours a
day) or severe cardiovascular disease (heart failure
Fig. 1 Study design: Schematic representation of the study workflow. WFR = weighed food records; T0, T1, T2, T3 = time of intervention; C-diet =
control diet PR-diet = polyphenol-rich diet
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class III or IV NYHA - New York Heart
Association)
 Antibiotic treatment in the last month
 Malignant tumor that required treatment in the
previous 2 years
Each subject enrolled has been assigned to an ID num-
ber. The encoding of samples is hidden to both the
investigators and the participants. All clinical and per-
sonal data, including the biological samples, of the sub-
jects involved in the study are collected and stored
anonymously.
Polyphenol-rich dietary protocol
In order to define the polyphenol-rich dietary protocol,
an initial estimation of nutrient and total polyphenol in-
take was performed through the analysis of the daily
menu provided at the OIC Foundation.
Subsequently, an identification of the specific
polyphenol-rich food products to be included in the diet
was carried out in order to consider not only the
amount and contribution of the different polyphenols
but also the food preparation in order to ensure their
bioavailability. In addition, an evaluation of conditions to
enable optimal texture (e.g. considering the use of
purées instead of the whole product) and an assessment
of the product acceptability by the target population was
also undertaken.
The polyphenol-rich dietary protocol (PR-diet) was fi-
nally developed by including in the C-diet 3 portions per
day of the following selected polyphenol-rich foods: ber-
ries and related products, blood orange, pomegranate,
green tea, Renetta apple, and dark chocolate.
A schematic plan of the type and serving sizes of
polyphenol-rich products consumed daily in the PR-diet
is shown in Table 2. The MaPLE polyphenol-rich foods
provided a mean of 724 mg/day of total polyphenols as
estimated by Folin-Ciocalteu analysis [26]. In addition,
the PR-diet and C-diet were kept comparable in terms
of energy intake and nutrient composition, and to
achieve this, polyphenol-rich products were substitute
for other comparable products (e.g. foods used for snack
or breakfast) and this continued across the entire period
of intervention.
Table 1 Standard protocol items: recommendations for interventional trials (SPIRIT)
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Information on potential adverse effects
Even though no reports of adverse effects due to a
polyphenol-rich diet had been registered or reported in the
literature, subjects were advised to annotate and communi-
cate any adverse symptom perceived during the interven-
tion period. Since green tea was selected within the
polyphenol-rich food sources to be used in the intervention
study, there was a comprehensive discussion to define the
dose to use. Green tea extract is a rich source of
epigallocatechin-3-gallate (EGCG) known for many differ-
ent protective effects; however, the intake of very high doses
of EGCG/green tea extracts as supplements has been re-
ported to cause liver toxicity. Recently, it has been proposed
an EGCG upper level (UL) based on human intervention
studies of 300mg EGCG/day in healthy adults [27]. The
proposed UL based on an ADI derived from animal toxicity
data was 322mg EGCG/day in a 70 kg adult. These values
are applicable to the oral exposure under fed conditions,
and consistent with those published by France [28] and
Italy [29]. In MaPLE, the dietary intervention provided 200
mg of green tea powder (i.e. 120mg total polyphenol in-
cluding about 100mg EGCG) 2 times per week. This quan-
tity was regarded as very likely to be safe taking into
account the target population and the contribution of other
food sources containing EGCC.
Assessment of food intake
Food intake before (enrollment phase) and during the
intervention periods was recorded through the evalu-
ation of OIC Foundation daily menus and the use of
WFRs. The daily menus, covering different seasons, were
analyzed to quantify nutrient and polyphenol content.
Moreover, the day before each time-point, a WFR was
completed and both nutrient and polyphenol intake
were estimated. At least 3-WFRs were completed during
each intervention period. Daily menus and WFRs were
Table 2 Daily plan of MaPLE polyphenol-rich food products: 3 portions per day are scheduled. Legend: º Chocolate powder was
dissolved in hot milk or water; *Green tea was prepared by solubilization of 200 mg of green tea extract in 200 ml of hot water.
+Renetta apple purée was prepared in controlled conditions and stored at − 18 °C.
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assessed using MetaDieta® (Me.Te.Da S.r.l., San Bene-
detto del Tronto, Italy) to estimate energy and nutrient
intake. Total polyphenol estimation was performed by
using the Phenol Explorer database (phenol-explorer.eu)
to provide estimates of polyphenol concentrations in
each food, and where there were no useful values, using
our proprietary data or values obtained from the litera-
ture. Total polyphenol content of the foods was esti-
mated directly using the Folin-Ciocalteau method [30].
Biological sampling
Blood, urine and fecal samples were collected at each time-
point as defined in Fig. 1. For blood drawing, a specific
vacutainer was used. Urine and fecal samples were collected
using specific containers designed for this purpose. An ali-
quot of each collected blood sample was immediately
stored at − 80 °C for microbiomic analyses. The remaining
blood was processed by centrifugation and then serum and
peripheral blood mononuclear cell (PBMC) fractions were
obtained, divided into aliquots and stored at 80 °C. Urine
and fecal sample were divided into aliquots, and all human
tissue samples were stored at − 80 °C until analysis.
In addition, a brush was used to collect an oral muco-
sal sample from each participant for further evaluation.
The brush with the collected tissue was stored in a cryo-
vial containing a buffered saline solution, which was
immediately frozen.
Outcome measurements
The primary selected outcome of the study was zonulin
as an IP marker, whereas other IP related markers (e.g.
CD14, calprotectin), inflammatory markers (CRP, TNF-
α, IL-6), oxidative stress and vascular function markers
(DNA damage, VCAM-1, ICAM-1), metabolomics and
microbiomics (16S rRNA gene quantification and taxo-
nomic profiling) were included as secondary outcomes
to support and validate our study hypothesis.
Anthropometric measurements
Body weight, height and BMI calculation were assessed at
the beginning and the end of each intervention period fol-
lowing the international guidelines of Lohman et al. [31].
Blood pressure
Each participant was monitored at the beginning and
the end of each intervention period measuring both sys-
tolic and diastolic pressure obtained in a resting, seated
position following the validated JNC 7 guidelines [32].
Metabolic and functional markers
At enrollment and at each time-point, metabolic and func-
tional parameters (i.e. glucose, insulin, lipid profile, liver
and renal function) were assessed by a standardized
validated protocol, using an automatic biochemical analyzer
(ILAB 650, Instrumentation Laboratory, Lexington, MA).
Low density lipoprotein cholesterol (LDL-C) concentration
was estimated using the Friedewald formula [33], while
non-high density lipoprotein cholesterol (non-high dens-
ity lipoprotein-cholesterol, HDL-C) was calculated by
subtracting HDL-C from total cholesterol (TC). The
HOMA-Index and Cockroft-Gault index were calcu-
lated according to the relevant formula [34, 35].
Intestinal permeability evaluation
Intestinal permeability was evaluated by quantifying
serum zonulin concentrations. Human zonulin is a pro-
tein (i.e. prehaptoglobin-2) released by enterocytes able
to promote the activation of the signaling transduction
pathway that cause tight junction protein disassembly
enabling potential bacterial factor translocation [36]. In
this study, zonulin serum levels were quantified using
the Immunodiagnostik® ELISA kit (Bensheim, Germany)
with samples collected in the selection phase and at the
beginning and the end of each intervention period.
Subjects selection based on IP was performed by consid-
ering reference values reported in the manufacturer’s in-
structions and data published on different target groups
[37–39]. Other IP related markers, such as serum CD14
and fecal calprotectin, were also quantified to support
the primary outcome.
Inflammatory markers
The concentrations of several markers related to inflam-
matory processes were quantified using specific ELISA
kits (R&D Systems, Biotechne, Abingdon, UK). CRP
(DCRP00), IL-6 (HS600B), TNF-α (HSTA00E) were
quantified in serum at the beginning and the end of each
intervention periods.
Vascular function markers
In order to assess vascular function, vascular cell adhe-
sion molecule-1 (VCAM-1) and intercellular adhesion
molecule-1 (ICAM-1) were quantified in serum samples
at each intervention time point using an ELISA kit
(Booster® from Vinci Biochem S.r.l., Vinci, Italy).
Oxidative stress marker (comet assay)
The levels of endogenous and oxidatively-induced DNA
damage, as markers of oxidative stress, were assessed in
PBMCs by the comet assay. The samples are collected
before and after each intervention period. Levels of en-
dogenous DNA damage were assessed using a specific
enzyme (formamidopyrimidine DNA glycosylase, FPG
sensitive sites) that can be used to detect 8-oxo-7,8-dihy-
dro-2′-deoxyguanosine (8-oxodG) and ring-opened for-
mamidopyrimidine nucleobases. Oxidatively-induced
DNA damage was measured by treating the cells with
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hydrogen peroxide and by evaluating the capacity of
cells to counteract an oxidative insult. Both Comet
assay protocols have been previously described by
Del Bo’ et al. [32].
Blood bacterial load and taxonomic profiling
Bacterial DNA quantification and sequencing reactions
were performed by Vaiomer SAS (Labège, France) using
optimized blood-specific techniques as described earlier
[40–43]. Specifically, DNA was extracted from 100 μl of
whole blood and quantified by quantitative PCR target-
ing the V3-V4 hypervariable regions of the bacterial 16S
rRNA gene with primers EUBF 5′-TCCTACGGGA
GGCAGCAGT-3′ and EUBR 5′ -GGACTACCAGGGT
ATCTAATCCTGTT-3′ [44]. The results are reported
as 16S rRNA gene copies per ng of total DNA and per
μl of blood. DNA from whole blood was also used for
16S rRNA gene taxonomic profiling using MiSeq Illu-
mina® technology (2 × 300 paired-end MiSeq kit V3, set
to encompass 467-bp amplicon) as previously described
[42, 43]. To determine bacterial community profiles, the
bar-coded Illumina paired reads were demultiplexed,
then single read sequences were trimmed and paired for
each sample independently into longer fragments; non-
specific amplicons (< 350 bases or > 500 bases) were re-
moved and remaining sequences clustered into operative
taxonomic units (OTUs) using FROGS v1.4.0 [45] with
default parameters; a taxonomic assignment was finally
performed against the Silva 128 Parc database. Bioinfor-
matics analysis of the sequencing data was also per-
formed using the Quantitative Insights Into Microbial
Ecology (QIIME) pipeline [46].
Fecal microbiota composition
All of the following steps were performed in-house at
QIB. Fecal samples were weighed into Lysing Matrix E
bead beating tubes (MPBio, Santa Ana, CA, USA) and
extraction was completed according to the manufac-
turer’s protocol for the FastDNA™ SPIN Kit for Soil
(MPBio) but extending the bead beating time to 3x60s.
DNA was quantified using a Qubit® 2.0 fluorometer
(Invitrogen, Carlsbad CA, USA), normalized to 5 ng/μl
and the V3/V4 region of the 16S rRNA was amplified
using the primers detailed below. Sequencing was per-
formed using a 600 cycle MiSeq v3 reagent kit (Illumina,
San Diego, CA, USA) giving approximately 100,000
reads per sample.
Bioinformatic analysis was conducted using VSEARCH
[47]; reads were merged, and primer sequences trimmed.
Reads were dereplicated and singletons removed. Prior
to Chimera removal, reads were clustered at 97% simi-
larity, de novo Chimera removal was performed using
the UCHIME algorithm [48] and the OTU table and
sequences were prepared. Data was subsequently ana-
lyzed using the phyloseq package in R [49].
Primers:
16S 341F – TCGTCGGCAGCGTCAGATGTGTATA
AGAGACAGCCTACGGGNGGCWGCAG.
16S 806R – GTCTCGTGGGCTCGGAGATGTGTA
TAAGAGACAGGACTACHVGGGTATCTAATCC.
In addition, taxonomic profiling was carried out
through shotgun sequencing. In brief, metagenomic
DNA isolated from fecal samples was sequenced using
an HiSeq instrument (Illumina, San Diego, CA) by Cos-
mosID (Rockville, MD, USA). Microbial community
composition was determined through the analysis of
shotgun metagenomic datasets with the CosmosID
metagenomic software as previously described [50].
Metabolomics
Urine samples collected prior and after each intervention
period were subjected to targeted metabolomics analysis
by applying the Quantitative Dietary Fingerprinting ap-
proach recently developed by González-Domínguez et al.
[51] with the aim of monitoring metabolite alterations
derived from the polyphenol-rich diet and to associate
these changes with improvements in clinical and bio-
chemical outcome measurements (e.g. IP evaluated
through zonulin levels, inflammatory and oxidative
stress markers, blood bacterial load). To this end, urine
samples were treated by solid phase extraction (SPE)
and subsequently analyzed by reversed-phase ultra-high-
performance liquid chromatography coupled to tandem
mass spectrometry (RP-UHPLC-MS/MS) to obtain a
comprehensive assessment of the urinary food metabo-
lome, with the simultaneous quantitative determination
of about 350 dietary derived metabolites. Complementa-
rily, plasma samples are also analyzed using a modifica-
tion of the previously described targeted metabolomics
approach, adapted to deal with the chemical complexity
of blood samples (high content of proteins and lipids)
and to enlarge the metabolomic coverage. This novel
method is based on a similar RP-UHPLC-MS/MS instru-
mental configuration that enables the simultaneous
measurement of both food intake biomarkers and en-
dogenous metabolites from multiple chemical classes
(ca. 1000 metabolites), including amino acids and deriva-
tives, biogenic amines, carbohydrates, organic and fatty
acids, vitamins and various lipid classes (e.g. acylcarni-
tines, steroid hormones, bile acids), among others. To
expand the method coverage towards the high-polarity
low molecular weight metabolome, an orthogonal hydro-
philic interaction liquid chromatography (HILIC)
procedure was also applied, covering a broad range of
polar metabolites (ca. 300 metabolites), comprising com-
mon and acetylated amino acids and microbiota deriva-
tives, low molecular weight organic acids (including
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short chain fatty acids and related compounds) and car-
bohydrates (e.g. sugars, conjugates and advanced glyca-
tion end products).
Sample size, randomisation, and statistics
According to data literature [38, 52] it was estimated
that 50 subjects were required to demonstrate an IP re-
duction of 30% with 80% power and 0.05 significance
and considering a 15% drop-out rate. Subjects were ran-
domly divided by using a computer random number
generator. The randomisation and allocation were per-
formed by a person not involved in the trial and blinded
to the participants, investigators/health care providers
and researchers involved in samples analysis. Statistical
analyses were performed by means of R statistic software
version 3.4.2. Particularly, the following statistical elabo-
rations will be performed to identify significant differ-
ences between treatments: (i) the analysis of variance
(ANOVA) with repeated measures, (ii) Wilcoxon paired
data test, (iii) Linear Mixed Model (LMM) analysis. In
addition, regression and correlation analyses (Spearman
and Kendal test) are carried out to highlight associations
between blood microbiomic data, fecal bacterial profiling
data, and physiological and biochemical data. When ap-
propriate, a post-hoc p-value adjustment is performed
using the Hochberg-Benjamin correction. Significance is
set at P ≤ 0.05; significance in the range 0.05 < P < 0.10 is
accepted as trend. Potential gender differences will be
also considered in all the analyses.
Discussion
There is growing evidence of a link between IP impair-
ment and increased inflammation [2]. Since aging is
characterized by low grade systemic inflammation it is
possible that an increase in IP may induce the activation
of inflammatory pathways and the immune system
caused by the translocation of intestinal microbes,
toxins, and/or nutritional components from the gut
lumen through the epithelium and into the bloodstream
[52]. While there is preliminary mechanistic evidence
obtained in animal models on the complex interaction
between age-associate microbial dysbiosis, IP and in-
flammation [5], the properties of the human intestinal
barrier, in the context of the ageing process, has not
been fully investigated [4]. The dietary pattern and the
intestinal microbial ecosystem homeostasis have been
addressed as potential key points for the development of
strategies to enable healthy aging. The manipulation
and/or improvement of the diet by increasing the con-
sumption of food bioactives (e.g. polyphenols) or specific
nutrients is recognized as a potential powerful tool to be
explored also in the context of IP. However, human
intervention studies are still very scarce, and most of
these performed using probiotics, prebiotic fibers and
dietary supplements [21].
By considering this premise, the MaPLE RCT here de-
scribed aimed to investigate whether a PR rich-diet can im-
prove the intestinal microbial ecosystem of older subjects
characterised by an increased IP. In addition, it is hypothe-
sized that such modulation could promote an overall benefi-
cial impact on IB function, a decreased IP and translocation
of inflammogenic bacterial factors in the blood.
The development and management of well-controlled
and adequately balanced dietary intervention studies is
not an easy task and it becomes even more difficult
when the target population is older subjects. Conse-
quently, the first task of the project was dedicated to the
optimization of the trial in order to overcome the pos-
sible problems related to compliance with the dietary in-
structions and to other relevant potential confounding
factors (e.g. periods of illness or the use of drugs that
may be relevant in this target group). For this reason,
the MaPLE RCT was planned in a residential area for
older people, since it provided a favourable and con-
trolled environment in which it was possible to optimize
and standardize most of the important experimental
conditions. For example, since outcome data from diet-
ary intervention studies are prone to being affected by
individual differences in diets and lifestyle behaviour
over time (e.g. during the two eight week periods of diet-
ary intervention), we were able to ensure both strict
compliance with the dietary intervention and a consist-
ent dietary pattern among participants by including the
polyphenol-rich products in their usual meals provided
by the residential home. In addition, the selection of
polyphenol-rich foods was based on three important
considerations: (i) That the types of foods selected were
largely universally liked, (ii) that the texture of the se-
lected products was suitable for older subjects (e.g. with
dentition challenges), and (iii) that the portion of food
would reliably provide a high dose of polyphenols. In
addition, weighed food intake was also assessed to pro-
vide us with data to allow accurate estimates of actual
nutrient and polyphenol intake in the two periods of
treatment (PR- and C- diet). This allowed a high degree
of control and substantially reduced between treatments
differences.
As regard the primary outcome, serum zonulin concen-
trations were used as the marker of IP because of the low
reliability and applicability of the multi-sugar test in the
older population (i.e. due to a high rate of incontinence
amongst the elderly participants and the need for adher-
ence to a strict dietary protocol before the test) [52].
It is also noteworthy that the MaPLE RCT is testing,
for the first time, the hypothesis that a dietary interven-
tion may modulate quantitatively the bacterial DNA in
bloodstream and qualitatively the blood microbiota
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composition. This should provide further evidence of
the impact of the dietary intervention on IP being poten-
tially associated with a reduction in translocation of bac-
terial factors. Other objectives of the MaPLE RCT are to
integrate microbiota profiling data with inflammation
and metabolomics data to improve understanding on the
impact of the dietary intervention. In addition, the inter-
individual response to the treatment will be investigated
and food metabolite profiling data will be exploited for
the identification of a set of potential biomarkers with
relevance in the context of preventing or treating im-
paired IP.
Finally, results will be pivotal for the development of new
dietary approaches and guidelines for managing IP related
conditions in the complex context of healthy aging.
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molecule-1; ICAM-1: Intercellular adhesion molecule-1; 8-oxodG: 8-oxo-7,8-
dihydro-2’-deoxiguanosine; QIIME: Quantitative insights into microbial
ecology; SPE: Solid phase extraction; HILIC: Orthogonal hydrophilic
interaction liquid chromatography; ANOVA: Analysis of variance; LMM: Linear
mixed model
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